Description: Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Home Page: www.lipocine.com
LPCN Technical Analysis
675 Arapeen Drive
Salt Lake City,
UT
84108
United States
Phone:
801 994 7383
Officers
| Name | Title |
|---|---|
| Dr. Mahesh V. Patel Ph.D. | Co-Founder, Interim Principal Financial Officer, Director, Pres & CEO |
| Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA | Corp. Sec. |
| Mr. Nachiappan Chidambaram Ph.D. | VP of Product Devel. |
| Mr. Logan Morse | VP of Sales, Marketing & Operations |
| Ms. Krista Fogarty | Principal Accounting Officer & Corp. Controller |
| Dr. Anthony DelConte M.D., M. D. | Chief Medical Director |
| Dr. George G. Nomikos M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 12.175 |
| Price-to-Book MRQ: | 0.9528 |
| Price-to-Sales TTM: | 2.3555 |
| IPO Date: | 2013-10-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |